Absci (ABSI) said Wednesday it has entered into a strategic collaboration with Advanced Micro Devices (AMD) to deploy AMD Instinct accelerators and ROCm software to power AI drug discovery workloads, including Absci's advanced de novo antibody design models.
As part of the collaboration, Advanced Micro Devices is also investing $20 million in Absci, structured as a private investment in public equity.
The collaboration will be featured at the 43rd Annual J.P. Morgan Healthcare Conference on Jan. 15, Absci said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。